

175

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Hans-Willi Jansen et al.

Application No.: 10/067,457

Filed: February 7, 2002

RECEIVED

APR 10 2002

Group Art Unit 1600/2900

Examiner: Not Yet Known

For: PROCESS FOR IDENTIFYING SUBSTANCES WHICH MODULATE THE  
ACTIVITY OF HYPERPOLARIZATION-ACTIVATED CATION CHANNELS

Assistant Commissioner for Patents  
Washington, D.C. 20231

SUBMISSION OF SUBSTITUTE DECLARATION

Sir:

Attached hereto is a Substitute Declaration/Power of Attorney of the inventors for this application. Please associate the attached Substitute Declaration/Power of Attorney with the application and use the information on the Substitute Declaration/Power of Attorney for future reference.

The attached Declaration/Power of Attorney is being submitted to include reference to the Preliminary Amendment filed with the application on February 7, 2002. Specifically, the Declaration/Power of Attorney filed with the application is a photocopy of the Declaration/Power of Attorney filed in parent application Serial No. 09/779,587. The present application was filed with a Preliminary Amendment that deleted unnecessary text from the application. In view of the Preliminary Amendment, a new Declaration/Power of Attorney, executed after review of the Preliminary Amendment was necessary. Such a Declaration/Power of Attorney is attached.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP


1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com



Applicants believe that no extensions of time or fees are due in connection with this submission. However, if any extensions of time or fees are due, please grant such extensions of time and charge any such fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

By:   
Matthew T. Latimer  
Reg. No. 44,024  
(202) 408-4495  
[matthew.latimer@finnegan.com](mailto:matthew.latimer@finnegan.com)

Date: April 9, 2002

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

| APPLICATION NUMBER | FILING/RECEIPT DATE | FIRST NAMED APPLICANT | ATTORNEY DOCKET NUMBER |
|--------------------|---------------------|-----------------------|------------------------|
| 10/067,457         | 02/07/2002          | Hans-Willi Jansen     | 02481.1732-01          |

CONFIRMATION NO. 8363

## FORMALITIES LETTER



\*OC000000007703572\*

23852  
FINNEGAN, HENDERSON, FARABOW, GARRETT &  
DUNNER LLP  
1300 I STREET, NW  
WASHINGTON, DC 20005

RECEIVED

APR 10 2002

Date Mailed: 03/22/2002

TECH CENTER 1600/2900

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*